A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy

被引：3

作者：

Hirai I. ^{[1
]}

Tanese K. ^{[1
]}

Obata S. ^{[1
]}

Funakoshi T. ^{[1
]}

机构：

[1] Department of Dermatology, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo

来源：

Indian Journal of Thoracic and Cardiovascular Surgery | 2017年 / 33卷 / 2期

关键词：

Primary malignant melanoma of the lung; Programmed cell death 1(PD-1); Tumor infiltrating lymphocytes (TIL);

D O I：

10.1007/s12055-017-0488-z

中图分类号：

学科分类号：

摘要：

Primary malignant melanoma of the lung (PMML) is an exceedingly rare type of melanoma. Here, we report a case of an 86-year-old Japanese woman who was diagnosed as PMML with subcarinal lymph node metastasis. She was treated with intravenous administration of programmed cell death-1 (PD-1) inhibitor, nivolumab. After the treatment, lymph node lesion regressed. The size of primary lesion was also controlled in combination with radiotherapy. In this case, two histological features were noted in the biopsy specimen that supported a response to nivolumab: membranous expression of programmed death ligand-1 (PD-L1) in tumor cells and dense scattered infiltration of CD8+ TILs. The clinical course of this case suggests that certain PMML cases may also respond to anti-PD-1 therapy. © 2017, Indian Association of Cardiovascular-Thoracic Surgeons.

引用

页码：173 / 175

页数：2

共 10 条

[1]

Jensen O.A., Egedorf J., Primary malignant melanoma of the lung, Scand J Respir Dis, 48, pp. 127-135, (1967)

[2]

Maeda R., Isowa N., Onuma H., Et al., Primary malignant melanoma of the lung with rapid progression, J Thorac Cardiovasc Surg, 57, pp. 671-674, (2009)

[3]

Gong L., Liu X.Y., Zhang W.D., Et al., Primary pulmonary malignant melanoma: a clinicopathologic study of two cases, Diagn Pathol, 7, (2012)

[4]

Iwai Y., Ishida M., Tanaka Y., Et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A, 99, pp. 12293-12297, (2002)

[5]

Wilson R.W., Moran C.A., Primary melanoma of the lung: a clinicopathologic and immunohistochemical study of eight cases, Am J Surg Pathol, 21, pp. 1196-1202, (1997)

[6]

Robert C., Long G.V., Brady B., Et al., Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, pp. 320-330, (2015)

[7]

Postow M.A., Callahan M.K., Wolchok J.D., Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, pp. 1974-1982, (2015)

[8]

Carbognin L., Pilotto S., Milella M., Et al., Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers, PLoS One, 10, (2015)

[9]

Peske J.D., Woods A.B., Engelhard V.H., Control of CD8 T-cell infiltration into tumors by vasculature and microenvironment, Adv Cancer Res, 128, pp. 263-307, (2015)

[10]

Erdag G., Schaefer J.T., Smolkin M.E., Et al., Immunotype and immunohistologic characteristics of tumor infiltrating immune cells are associated with clinical outcome in metastatic melanoma, Cancer Res, 72, pp. 1070-1080, (2012)

← 1 →